

CONTENTS

List of figures	iii
List of tables	vi
Acknowledgement	vii
Summary	viii
Certificate	ix
Declaration	x
Dedication	xi

CHAPTER 1

1. INTRODUCTION

1.1	Chromones	1
1.2	Importance of chromones in medicinal chemistry	2
1.3	Biological role of copper	5
1.4	Effect of metal complexation on biological activity	10
1.5	Physical techniques used for characterization	14
1.5.1	Infrared spectroscopy	14
1.5.2	Nuclear magnetic resonance	15
1.5.3	Electronic absorption spectra	15
1.5.4	Magnetic moments	17
1.5.5	Conductivity measurements	19
1.5.6	Thermal analysis	19
1.5.7	Micro analysis	21
1.5.8	Anti-microbial activity	21
1.6	Aims of the study	24

CHAPTER 2

EXPERIMENTAL

2.1	Materials	25
2.2	Method	26
2.2.1	Preparation of ligands	26

2.2.2	Preparation of Cu (II) complexes	28
2.3	Antibacterial activity studies	30
2.3.1	Sterilization of equipments	30
2.3.2	Media preparation and challenge test	30
2.3.3	Preparation of cultures	31
2.3.4	Determination of antibacterial activity by paper disc diffusion method	32
2.3.5	Determination of MIC	34

CHAPTER 3

RESULTS AND DISCUSSION

3.1	Preparation of ligands	38
3.1.1	Characterization of ligands (1-17)	38
3.1.1.1	Solubility	38
3.1.1.2	Electronic absorption spectra	38
3.1.1.3	Infrared spectra	41
3.1.1.4	¹ H-NMR spectra	44
3.1.1.5	Mass spectra	48
3.2	Preparation of Cu (II) complexes	58
3.2.1	Characterization of Cu (II) complexes (18-29)	58
3.2.1.1	Solubility	61
3.2.1.2	Micro-analytical data	61
3.2.1.3	Magnetic moments	61
3.2.1.4	Conductivity measurements	61
3.2.1.5	Water contents	61
3.2.1.6	Thermal analysis	63
3.2.1.7	Electronic absorption spectra	83
3.2.1.8	FT-IR spectra	83
3.2.1.9	Proposed structures	86
3.3	Antibacterial studies of the ligands and Cu (II) complexes	92
3.3.1	Preliminary screening	92
3.3.2	Minimum inhibitory concentration	96

List of figures

Fig.		Page
1	Structure of chromone	1
2	Structure of 3-formylchromone	2
3	Geometries of Cu (II) in complexes	9
4	Structure and fragmentation pattern of ligand 1 (3,5-dichloro-2-hydroxyphenyl)[2-(4-hydroxyphenyl)-1,3,4-oxadiazepin-6-yl]methanone	49
5	Structure and fragmentation pattern of ligand 2 [2-(4-bromophenyl)-1,3,4-oxadiazepin-6-yl](3,5-dichloro-2-hydroxyphenyl)methanone	49
6	Structure and fragmentation pattern of ligand 3 [2-(4-chlorophenyl)-1,3,4-oxadiazepin-6-yl](3,5-dichloro-2-hydroxyphenyl)methanone	50
7	Structure and fragmentation pattern of ligand 4 [2-(4-aminophenyl)-1,3,4-oxadiazepin-6-yl](3,5-dichloro-2-hydroxyphenyl)methanone	50
8	Structure and fragmentation pattern of ligand 5 (3,5-dichloro-2-hydroxyphenyl)(2-pyridin-4-yl-1,3,4-oxadiazepin-6-yl)methanone	51
9	Structure and fragmentation pattern of ligand 6 (3,5-dichloro-2-hydroxyphenyl)(2-pyridin-3-yl-1,3,4-oxadiazepin-6-yl)methanone	51
10	Structure and fragmentation pattern of ligand 7 (3,5-dichloro-2-hydroxyphenyl)[1-(2,3,5,6-tetrafluorophenyl)-1 <i>H</i> -pyrazol-4-yl]methanone	52
11	Structure and fragmentation pattern of ligand 8 (3,5-dichloro-2-hydroxyphenyl)[1-(2,5-difluorophenyl)-1 <i>H</i> -pyrazol-4-yl]methanone	52
12	Structure and fragmentation pattern of ligand 9 (3,5-dichloro-2-hydroxyphenyl)[1-(2,5-dichlorophenyl)-1 <i>H</i> -pyrazol-4-yl]methanone	53
13	Structure and fragmentation pattern of ligand 10 (3,5-dichloro-2-hydroxyphenyl)[1-(3-methylphenyl)-1 <i>H</i> -pyrazol-4-yl]methanone	53
14	Structure and fragmentation pattern of ligand 11 4-[4-(3,5-dichloro-2-hydroxybenzoyl)-1 <i>H</i> -pyrazol-1-yl]benzoic acid	54
15	Structure and fragmentation pattern of ligand 12 (3,5-dichloro-2-hydroxyphenyl)[1-(4-methoxyphenyl)-1 <i>H</i> -pyrazol-4-yl]methanone	54
16	Structure and fragmentation pattern of ligand 13 (2-amino-1,3,4-thiadiazepin-6-yl)(3,5-dichloro-2-hydroxyphenyl)methanone	55
17	Structure and fragmentation pattern of ligand 14 (2-anilino-1,3,4-thiadiazepin-6-yl)(3,5-dichloro-2-hydroxyphenyl)methanone	55
18	Structure and fragmentation pattern of ligand 15 (2-anilino-1,3,4-oxadiazepin-6-yl)(3,5-dichloro-2-hydroxyphenyl)methanone	56

19	Structure and fragmentation pattern of ligand 16 (3,5-dichloro-2-hydroxyphenyl)[2-(diphenylamino)-1,3,4-oxadiazepin-6-yl]methanone	56
20	Structure and fragmentation pattern of ligand 17 (2-amino-1,3,4-oxadiazepin-6-yl)(3,5-dichloro-2-hydroxyphenyl)methanone	57
21	TGA, DTA and DSC curves of Cu (II) complex 18	64
22	TGA, DTA and DSC curves of Cu (II) complex 19	65
23	TGA, DTA and DSC curves of Cu (II) complex 20	66
24	TGA, DTA and DSC curves of Cu (II) complex 21	67
25	TGA, DTA and DSC curves of Cu (II) complex 22	68
26	TGA, DTA and DSC curves of Cu (II) complex 23	69
27	TGA, DTA and DSC curves of Cu (II) complex 24	70
28	TGA, DTA and DSC curves of Cu (II) complex 25	71
29	TGA, DTA and DSC curves of Cu (II) complex 26	72
30	TGA, DTA and DSC curves of Cu (II) complex 27	73
31	TGA, DTA and DSC curves of Cu (II) complex 28	74
32	TGA, DTA and DSC curves of Cu (II) complex 29	75
33	TGA, DTA and DSC curves of Cu (II) complex 30	76
34	TGA, DTA and DSC curves of Cu (II) complex 31	77
35	TGA, DTA and DSC curves of Cu (II) complex 32	78
36	TGA, DTA and DSC curves of Cu (II) complex 33	79
37	TGA, DTA and DSC curves of Cu (II) complex 34	80
38	Proposed structure of Cu (II) complex 18	86
39	Proposed structure of Cu (II) complex 19	86
40	Proposed structure of Cu (II) complex 20	87
41	Proposed structure of Cu (II) complex 21	87
42	Proposed structure of Cu (II) complex 22	87

43	Proposed structure of Cu (II) complex 23	88
44	Proposed structure of Cu (II) complex 24	88
45	Proposed structure of Cu (II) complex 25	88
46	Proposed structure of Cu (II) complex 26	89
47	Proposed structure of Cu (II) complex 27	89
48	Proposed structure of Cu (II) complex 28	89
49	Proposed structure of Cu (II) complex 29	90
50	Proposed structure of Cu (II) complex 30	90
51	Proposed structure of Cu (II) complex 31	90
52	Proposed structure of Cu (II) complex 32	91
53	Proposed structure of Cu (II) complex 33	91
54	Proposed structure of Cu (II) complex 34	91

List of tables

Tables		Page
1	List of chemicals	25
2	Composition of tryptic soy broth	31
3	Composition of tryptic soy agar	33
4	Drug dilutions prepared	35
5	Serial dilutions and concentrations	37
6	Physical and UV-Visible spectral data of the ligands	39
7	FT-IR spectral data of the ligands (1-12)	42
8	FT-IR spectral data of the ligands(13-17)	43
9	NMR spectral data of the ligands	45
10	Physical data of Cu (II) complexes	59
11	Micro-analytical and UV-Visible spectral data of Cu (II) complexes	60
12	Magnetic moment, conductivity and water data of Cu (II) complexes	62
13	Thermal data of Cu (II) complexes	81
14	FT-IR spectral data of Cu (II) complexes (19-29)	84
15	FT-IR spectral data of Cu (II) complexes (30-34)	85
16	Antibacterial activity data of the prepared ligands and their Cu (II) complexes	93
17	MIC data of the selected compounds	97

REFERENCES

101